CXCR2 and glioblastoma: Additionally, CXCR2, the physiological receptor for CXCL8 has been shown to improve CAR T cell therapy preclinically [97], now being tested in a phase 1 study targeting glioblastoma (NCT05353530) where an anti-CD70 CAR T cell is additionally modified to express CXCR2.